EXEL
Exelixis Inc.
Latest News for EXEL
Exelixis ($EXEL) announced an update on their ongoing clinical study. Exelixis has launched a new Phase 2 trial called “A Phase 2, Single-Arm, Mult......
Exelixis ($EXEL) announced an update on their ongoing clinical study. Exelixis has launched a new Phase 2 trial called “A Phase 2, Single-Arm, Mult......
In a report released yesterday, from Guggenheim maintained a Hold rating on Exelixis. The company’s shares closed yesterday at $48.70. The word on ......
Exelixis (($EXEL)) has held its Q1 earnings call. Read on for the main highlights of the call. Exelixis struck an upbeat tone on its latest earning......
Exelixis (($EXEL)) has held its Q1 earnings call. Read on for the main highlights of the call. Exelixis struck an upbeat tone on its latest earning......
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)......
Exelixis ( ($EXEL) ) just unveiled an announcement. On May 5, 2026, Exelixis reported first quarter 2026 revenues of $610.8 million, up from $555.4......
News data is sourced from MarketXLS API and updated regularly.
Showing 7 of 7 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EXEL | $49.94 | -0.4% | 877.53K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |